Intestinal health | FIV | Magazine https://fivmagazine.com Mon, 16 Feb 2026 17:00:00 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.5 Cannabis for irritable bowel syndrome: IBS, CBD & intestinal pain https://fivmagazine.com/cannabis-for-irritable-bowel-syndrome-ibs-cbd-intestinal-pain/ Mon, 16 Feb 2026 17:00:00 +0000 https://fivmagazine.de/cannabis-for-irritable-bowel-syndrome-ibs-cbd-intestinal-pain/ Most importantly, IBS affects 10-15% of the population. IBS patients have increased FAAH activity and lower anandamide levels in the intestine – a measurable ECS deficit directly at the site of the symptoms.
At a glance:

  • IBS patients have increased FAAH activity and lower anandamide levels in the gut – measurable ECS deficit
  • CB1 on enteric neurons: THC reduces hypermotility and pain sensitivity directly in the gut
  • CBD desensitizes TRPV1 pain receptors in the gut – less visceral hypersensitivity

Irritable bowel syndrome and the endocannabinoid system

Irritable bowel syndrome (IBS) is the most common functional gastrointestinal disorder – affecting 10-15% of the population. IBS without cause in terms of organic pathology is characterized by abdominal pain, altered stool frequency (diarrhoea, constipation or mixed) and flatulence. The endocannabinoid system is densely distributed throughout the gastrointestinal tract and regulates precisely those functions that are disrupted in IBS.

ECS in the intestine: Gut Brain Axis

The enteric nerve (the “abdominal brain”) contains more neurons than the spinal cord and is closely connected to the ECS. CB1 receptors are located in:
– Enteric neurons (motility control)
– Intestinal epithelial cells (barrier function, secretion)
– Immune cells (mast cells, macrophages in the intestinal wall)
– Afferent sensory nerve fibers (pain and distension)

Endocannabinoids (anandamide, 2-AG) regulate gastrointestinal motility (CB1 inhibits excessive peristalsis), intestinal permeability and pain signals from the intestine.

Clinical endocannabinoid deficit theory in IBS

Ethan Russo’s CEDS theory (2004, 2016) describes IBS as part of a clinical endocannabinoid deficit – alongside migraine and fibromyalgia. Evidence:
– IBS patients have increased FAAH activity → lower anandamide levels
– CB1 polymorphisms associated with IBS severity and abdominal pain
– Anandamide infusion in IBS patients reduces visceral hypersensitivity (animal model)

Study situation: Cannabis and IBS

Study Design Result
Wong et al. 2012 (Clin Pharmacol Ther) RCT, n=36, CB1 agonist (delta-9-THC) vs. placebo, IBS-D (diarrhea-dominant) THC significantly reduced gastrointestinal transit time; reduced colonic distension pain; no effect on inflammation
Klooker et al. 2011 (good) RCT, n=75, dronabinol 2.5 mg vs. placebo, visceral hypersensitivity Dronabinol significantly reduces visceral pain hypersensitivity in IBS patients
Andresen et al. 2016 (Clin Transl Gastroenterol) RCT, n=196, CB1 agonist (rimonabant was already CB1 antagonist negative), cannabidiol More complex situation: CB1 antagonism increases IBS – indirectly proves CB1 agonism as a therapeutic principle
Thakur et al. 2014 (J Physiol Pharmacol) Overview, Cannabis + IBS Cannabis consistent improvement in IBS-C (constipation-dominant) and IBS-D through CB1-mediated motility regulation

IBS types and cannabis

IBS-D (diarrhea-dominated): CB1 activation slows intestinal transit → less uncontrolled diarrhea. THC in IBS-D has an antidiarrheal effect (similar to loperamide, but via a different mechanism).

IBS-C (constipation-dominant): Too much CB1 activation can exacerbate constipation. Lower doses of THC + CBD may be better balanced for IBS-C.

IBS-M (mixed): CBD-first: less direct CB1 influence on motility, but anxiolysis (anxiety as an IBS trigger) and inhibition of inflammation.

CBD-specific effect on IBS

CBD works on IBS in several ways:
– Visceral hypersensitivity: TRPV1 desensitization in intestinal nerve fibers → less pain with normal stretching
– Anxiety: Gut-brain axis – anxiety and stress consistently exacerbate IBS. CBD anxiolysis via 5-HT1A can improve IBS symptoms via the psychosomatic route
– Intestinal permeability: CBD strengthens tight junctions in the intestinal epithelium → reduces leaky gut effects

Study highlight: Nabilone (synthetic THC) significantly improved pain and quality of life in IBS in an RCT. IBS patients have increased FAAH activity and lower anandamide levels in the gut – the pharmacological background for cannabis self-medication in IBS.
More on the topic:

FAQ: Cannabis for irritable bowel syndrome

Summary

IBS and ECS are closely linked: CB1 regulates intestinal motility, visceral pain and permeability. Clinical RCTs show dronabinol and THC significantly reduce visceral hypersensitivity and intestinal transit time. CBD acts via anxiolysis, TRPV1 and tight junction protection. IBS-D benefits from THC (antidiarrheal), IBS-C requires more cautious dosing. Cannabis for fibromyalgia and cannabis for anxiety cover the most common IBS comorbidities.

Cannabis prescription online? Our teleclinic comparison shows all 31 providers in direct comparison – with prices, waiting times and real reviews. Free and independent.
]]>